4.5 Article

Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms A review of the literature and a long-standing experience of a referral center

期刊

DIGESTIVE AND LIVER DISEASE
卷 48, 期 3, 页码 231-241

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.dld.2015.11.017

关键词

Biliary tract cancer; Diagnosis; Therapy

向作者/读者索取更多资源

In the oncology landscape, cholangiocarcinoma is a challenging disease in terms of both diagnosis and treatment. Besides anamnesis and clinical examination, a definitive diagnosis of cholangiocarcinoma should be supported by imaging techniques (US, CT, MRI) and invasive investigations (ERC or EUS with brushing and FNA or US or CT-guided biopsy) followed by pathological confirmation. Surgery is the main curative option, so resectability of the tumour should be promptly assessed. Moreover, jaundice must be evaluated at the outset because biliary tract decompression with drainage and stent placement may be required. If the patient is resectable, pre-operative assessment of postoperative liver function is mandatory. After a curative resection, an adjuvant therapy may be administered. Otherwise, in cases with macroscopic residual disease after surgery or locally recurrent or unresectable cholangiocarcinoma at the diagnosis, first-line chemotherapy is the preferred strategy, possibly associated with radiotherapy and/or locoregional treatments. As the diagnostic and therapeutic pathway for cholangiocarcinoma can be declined in different modalities, patients should be promptly referred to a multidisciplinary team in a tertiary centre, familiar with this rare but lethal disease. Hence, the aim of the present paper is to focus on diagnostic and therapeutic algorithms based on the common guidelines and also on the clinical practice of multispecialist expert groups. (C) 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma

Carlo Sposito, Francesca Ratti, Alessandro Cucchetti, Francesco Ardito, Andrea Ruzzenente, Stefano Di Sandro, Marianna Maspero, Giorgio Ercolani, Fabrizio Di Benedetto, Alfredo Guglielmi, Felice Giuliante, Luca Aldrighetti, Vincenzo Mazzaferro

Summary: This study aimed to determine whether lymphadenectomy improves long-term outcomes in patients with clinically node-negative intrahepatic cholangiocarcinoma (iCCA). The results showed that adequate lymphadenectomy significantly improved survival outcomes for patients with clinically node-negative iCCA who were found to be node-positive at pathology. Therefore, routine use of adequate lymphadenectomy is recommended for patients with clinically node-negative iCCA.

JOURNAL OF HEPATOLOGY (2023)

Article Surgery

ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma

Vittoria Matilde Piva, Maria Caterina De Grandis, Irene Sole Zuin, Valentina Angerilli, Floriana Nappo, Rita Alfieri, Selma Ahcene Djaballah, Sabina Murgioni, Francesca Bergamo, Matteo Fassan, Michele Valmasoni, Sara Lonardi

Summary: This review summarizes the current evidence on the use of liquid biopsy in gastroesophageal cancer, focusing on the detection of ctDNA in the postoperative setting and its potential role as a guide for treatment decision.

UPDATES IN SURGERY (2023)

Article Oncology

Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa Ramos, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini

Summary: This real-world study investigates the association between the prognostic nutritional index (PNI) and clinical outcomes in HCC patients treated with atezolizumab plus bevacizumab. The study shows that high PNI is associated with longer overall survival and progression-free survival.

ONCOLOGY (2023)

Article Oncology

Antigen rapid diagnostic test monitoring for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients: Is it cost-effective?

Mario Caccese, Anna Maria Saieva, Valentina Guarneri, Sara Lonardi, Massimo Cacco, Vanna Chiarion Sileni, Michele Gottardi, Eleonora Mioranza, Francesca Bergamo, Antonella Brunello, Vittorina Zagonel, Patrizia Benini

Summary: Routine testing for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients during treatment did not appear to be cost-effective. Out of 2439 cancer patients screened, only 2.17% tested positive, and 92.5% had their cancer treatment discontinued as a precaution.

CANCER MEDICINE (2023)

Article Oncology

'Potentially curative therapies' for hepatocellular carcinoma: how many patients can actually be cured?

Alessandro Cucchetti, Omar Elshaarawy, Guohong Han, Charing C. N. Chong, Carla Serra, Joanne Marie O'Rourke, Richard Crew, Cristina Felicani, Giorgio Ercolani, Tahir Shah, Arndt Vogel, Paul B. S. Lai, Philip J. Johnson

Summary: This study developed a statistical model to predict cure after ablation and compared the curative potential of different therapies. The cure fraction for HCC treated with ablation was found to be around 20% to 30%, similar to resection but inferior to transplantation.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma

Francesco Pierantoni, Michele Dionese, Umberto Basso, Eleonora Lai, Nicolo Cavasin, Elisa Erbetta, Alvise Mattana, Davide Bimbatti, Vittorina Zagonel, Sara Lonardi, Marco Maruzzo

Summary: Analyzing clinical data of 72 mUC patients treated with ICIs, we found that fT3/fT4 ratio is a strong prognostic factor for progression-free survival and overall survival. The prognostic role of fT3/fT4 ratio is independent from other established prognostic factors.

CLINICAL GENITOURINARY CANCER (2023)

Article Oncology

Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Francesca Salani, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Marta Schirripa, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini

Summary: This study analyzed the efficacy of atezolizumab plus bevacizumab versus Lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B. The results showed that Lenvatinib had a longer overall survival (OS) compared to atezolizumab plus bevacizumab in patients with CP B HCC.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Oncology

Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study

Roberto Moretto, Daniele Rossini, Aurelie Catteau, Carlotta Antoniotti, Mirella Giordano, Alessandra Boccaccino, Clara Ugolini, Agnese Proietti, Veronica Conca, Alboukadel Kassambara, Filippo Pietrantonio, Lisa Salvatore, Sara Lonardi, Stefano Tamberi, Emiliano Tamburini, Anello Marcello Poma, Jacques Fieschi, Gabriella Fontanini, Gianluca Masi, Jerome Galon, Chiara Cremolini

Summary: The expression of tumor-infiltrating lymphocytes (TILs), Immunoscore, Immunoscore-IC, and programmed death ligand-1 (PD-L1) can predict the efficacy of immune-checkpoint inhibitors (ICIs) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Oncology

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio

Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Oncology

Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy

Andrea Casadei-Gardini, Francesco Leone, Giovanni Brandi, Mario Scartozzi, Nicola Silvestris, Daniele Santini, Luca Faloppi, Massimo Aglietta, Maria Antonietta Satolli, Alessandro Rizzo, Sara Lonardi, Giuseppe Aprile, Lorenzo Fornaro

Summary: Cholangiocarcinoma is a rare tumor that affects the liver biliary tree with poor prognosis. This study analyzed a large dataset of cholangiocarcinoma patients receiving systemic chemotherapy over a period of almost 20 years to understand their survival trends.

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability- high metastatic colorectal cancer treated with immune checkpoint inhibitors

Paolo Manca, Francesca Corti, Rossana Intini, Giacomo Mazzoli, Rosalba Miceli, Marco Maria Germani, Francesca Bergamo, Margherita Ambrosini, Eleonora Cristarella, Riccardo Cerantola, Chiara Boccaccio, Gianmarco Ricagno, Filippo Ghelardi, Giovanni Randon, Giuseppe Leoncini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio

Summary: Immune checkpoint inhibitors (ICIs) are the standard treatment for patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). Tumour mutational burden (TMB) is a promising biomarker for predicting treatment outcomes.

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action

Lorenzo Fornaro, Sara Lonardi, Silvia Catanese, Floriana Nappo, Filippo Pietrantonio, Antonio Pellino, Valentina Angerilli, Francesca Signorini, Francesca Salani, Sabina Murgioni, Ioana Ancuta Neculaescu, Rossella Bruno, Caterina Vivaldi, Gianmarco Ricagno, Gianluca Masi, Francesca Bergamo, Clara Ugolini, Matteo Fassan

Summary: Different methods of evaluation for mismatch repair proteins and microsatellite instability-high (MSI-H) status in gastric and gastroesophageal adenocarcinoma can lead to inconsistent results between endoscopic biopsies and surgical samples. Strategies to improve reliability of assessment should focus on tissue collection and management during endoscopy, as well as training of dedicated gastrointestinal pathologists within the multidisciplinary team.

GASTRIC CANCER (2023)

Article Gastroenterology & Hepatology

European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data and Global Burden of Disease Study 2019

Alessandro Cucchetti, Philip Johnson, Gabriele Capurso, Stefano Crippa, Carlo Alberto Pacilio, Carlo Fabbri, Massimo Falconi, Giorgio Ercolani

Summary: The aim of this study was to explore the correlation between incidence and mortality of pancreatic cancer and healthcare indicators in 36 European countries. The results showed that both incidence and mortality were increasing, and they were strongly positively correlated. Higher health expenditure, availability of beds and medical technology, as well as the number of practicing doctors were related to higher incidence. On the other hand, lower mortality was associated with indicators such as outpatient curative care expenditure, the number of pet scanners, and radiation therapy equipment. The study highlights the impact of healthcare environment on pancreatic cancer incidence and mortality.

PANCREATOLOGY (2023)

Article Surgery

Differences in the learning curve of robotic transabdominal preperitoneal inguinal hernia repair according to surgeon's robotic experience

L. Solaini, D. Cavaliere, G. Rocco, A. Avanzolini, D. Di Pietrantonio, G. Ercolani

Summary: The study aims to analyze the learning curve of each step of robotic transabdominal pre-peritoneal inguinal hernia repair (rTAPP) in two surgeons with varying degrees of expertise with the robotic platform but no experience with laparoscopic hernia repair. It was found that there was a learning phase followed by a gradual improvement in operative time and outcomes. The learning phase of rTAPP surgery may vary between 20 and 35 cases, depending on the surgeon's experience in robotic surgery.

HERNIA (2023)

暂无数据